Results from COVID-19 postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccine for melanoma and pregnant individuals to help protect against RSV complications in infants.
Please login or register first to view this content.